Skip to Content
Merck
CN

A6883

Atropine methyl bromide

≥99% (TLC), powder

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C18H26NO3 · Br
CAS Number:
Molecular Weight:
384.31
UNSPSC Code:
12352200
PubChem Substance ID:
EC Number:
220-700-1
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


assay

≥99% (TLC)

form

powder

color

white to off-white

solubility

H2O: 50 mg/mL

SMILES string

Br.C[N]1(C)[C@@H]2CC[C@H]1C[C@@H](C2)OC(=O)C(CO)c3ccccc3

InChI

1S/C18H26NO3.BrH/c1-19(2)14-8-9-15(19)11-16(10-14)22-18(21)17(12-20)13-6-4-3-5-7-13;/h3-7,14-17,20H,8-12H2,1-2H3;1H/t14-,15+,16?,17?;

InChI key

YBFLMRSYEWDJEJ-ZNHDNBJUSA-N

Biochem/physiol Actions

Competitive muscarinic acetylcholine receptor antagonist that does not cross the blood-brain barrier.


pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

13 - Non Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



M M Knuepfer et al.
The American journal of physiology, 276(1 Pt 2), R103-R112 (1999-01-14)
It has been suggested that toxicity to cocaine is related to the relative rate of cocaine metabolism by cholinesterases and to activation of cholinergic receptors either directly or by reflex mechanisms. We examined these possibilities by altering cholinesterase activity and
Timothy A Yap et al.
Molecular cancer therapeutics, 10(2), 360-371 (2010-12-31)
AKT is frequently deregulated in cancer, making it an attractive anticancer drug target. CCT128930 is a novel ATP-competitive AKT inhibitor discovered using fragment- and structure-based approaches. It is a potent, advanced lead pyrrolopyrimidine compound exhibiting selectivity for AKT over PKA
G J Kirouac et al.
The American journal of physiology, 273(6 Pt 2), H2549-H2557 (1998-01-22)
Experiments were done in alpha-chloralose-anesthetized, paralyzed, and artificially ventilated rats to investigate the effect of L-glutamate (Glu) stimulation of the substantia nigra (SN) and ventral tegmental area (VTA) on arterial pressure (AP) and heart rate (HR). Glu stimulation of the